NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP

Rank in Stocks #19739
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Share Price
$0.8499
Last synced: 2026-11-13
Market Cap
$98.35M
Change (1 day)
2.40%
Change (1 year)
-79.52%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for NovaBridge Biosciences (NBP)
EPS as of June 2026 TTM: $-0.58
According to NovaBridge Biosciences's latest financial reports, its current EPS (TTM) is $-0.58. At the end of 2025 the company had an EPS of $-1.10, a decrease compared to its 2024 EPS of $-0.61.
EPS history for NovaBridge Biosciences from 2017 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.58 -47.27%
2025 $-1.10 80.03%
2024 $-0.61 -75.45%
2023 $-2.49 -43.48%
2022 $-4.40 -8.82%
2021 $-4.83 -491.01%
2020 $1.24 -133.69%
2019 $-3.67 264.45%
2018 $-1.01 27.58%
2017 $-0.79 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 53.45%
US
$15.66 -2,800.00%
US
$-7.07 1,118.97%
US
$-5.29 812.07%
AU
$12.73 -2,295.21%
BE

Questions about NovaBridge Biosciences's earnings per share (EPS)

What is NovaBridge Biosciences's earnings per share (EPS)?

NovaBridge Biosciences's earnings per share (EPS) over the last twelve months is $-0.58, as of Jun 2026.

What was NovaBridge Biosciences's earnings per share (EPS) in 2025?

In 2025, NovaBridge Biosciences's earnings per share (EPS) was $-1.10, compared with $-0.61 in 2024.

How has NovaBridge Biosciences's earnings per share (EPS) changed since 2020?

From 2020 to 2025, NovaBridge Biosciences's earnings per share (EPS) was highest in 2020 ($1.24) and lowest in 2021 ($-4.83).

How does NovaBridge Biosciences's earnings per share (EPS) compare with similar companies?

NovaBridge Biosciences's earnings per share (EPS) ($-0.58) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.